儿童牛皮:现代治疗中的生物药物和口服小分子抑制剂
Alexandra Firek1, Leslie Castelo-Soccio1
1Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland.
JAAD reviews
|February 14, 2025
概括
包括生物药物和口服小分子在内的新疗法正在改善儿科牛皮治疗. 需要更多的研究来优化患有这种疾病的儿童的结果.
科学领域:
- 儿科皮肤病学 儿科皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 牛皮会影响儿童,影响他们的生活质量.
- 传统的治疗方法对儿科患者有局限性.
- 新兴疗法为治疗儿科牛皮提供了新的希望.
研究的目的:
- 为提供当前儿科牛皮治疗方法的概述.
- 专注于越来越多地使用生物制剂和口服小分子.
- 根据剂量,安全性和疗效的措施来评估治疗选择.
主要方法:
- 审查当前的文献和临床试验.
- 对儿科特异性和成人试验数据的分析.
- 使用牛皮区域严重性指数 (PASI) 和儿童皮肤病生命质量指数 (CDLQI) 评估治疗结果.
主要成果:
- 生物制剂和口服小分子代表了不断扩大的治疗选择.
- 专门针对儿童的临床试验正在增加,但仍然有限.
- 成人试验数据可以为潜在的儿科治疗策略提供信息.
结论:
- 目前的治疗方法正在不断发展,生物药物和口服药物的使用量显著增加.
- 显著需要更多以儿科为重点的研究和试验.
- 进一步的研究将完善治疗决策,并改善儿科牛皮患者的治疗结果.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Metabolism
410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Pharmacokinetics in Pediatric Patients: Drug Excretion
408
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
408
Acne Infection
94
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
94


